Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer

Charles Swanton, Zoltan Imre Szallasi, James D. Brenton, Julian Downward

    Research output: Contribution to journalJournal articleResearchpeer-review

    216 Downloads (Pure)

    Abstract

    The widespread introduction of high throughput RNA interference screening technology has revealed tumour drug sensitivity pathways to common cytotoxics such as paclitaxel, doxorubicin and 5-fluorouracil, targeted agents such as trastuzumab and inhibitors of AKT and Poly(ADP-ribose) polymerase (PARP) as well as endocrine therapies such as tamoxifen. Given the limited power of microarray signatures to predict therapeutic response in associative studies of small clinical trial cohorts, the use of functional genomic data combined with expression or sequence analysis of genes and microRNAs implicated in drug response in human tumours may provide a more robust method to guide adjuvant treatment strategies in breast cancer that are transferable across different expression platforms and patient cohorts.
    Original languageEnglish
    JournalBreast Cancer Research (Online Edition)
    Volume10
    Issue number5
    Pages (from-to)214
    ISSN1465-5411
    DOIs
    Publication statusPublished - 2008

    Fingerprint

    Dive into the research topics of 'Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer'. Together they form a unique fingerprint.

    Cite this